Published in J Steroid Biochem Mol Biol on December 01, 2000
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. Br J Cancer (2011) 1.17
Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci U S A (2002) 1.14
Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. Am J Clin Exp Urol (2015) 1.05
Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride. J Steroid Biochem Mol Biol (2012) 1.02
Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation. Int J Biol Sci (2014) 0.85
Pregnenolone activates CLIP-170 to promote microtubule growth and cell migration. Nat Chem Biol (2013) 0.84
Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression. Endocrinology (2014) 0.82
Structure-based virtual screening and identification of a novel androgen receptor antagonist. J Biol Chem (2012) 0.80
Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer. Adv Ther (2013) 0.79
Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts. Prostate Cancer Prostatic Dis (2015) 0.78
Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy. Nat Rev Urol (2015) 0.77
Pterostilbene-isothiocyanate conjugate suppresses growth of prostate cancer cells irrespective of androgen receptor status. PLoS One (2014) 0.76
Abiraterone for the Treatment of Advanced Prostate Cancer. Int J Target Ther Cancer (2012) 0.75
Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer. Asian J Urol (2016) 0.75
A controlled trial of physician counseling to promote the adoption of physical activity. Prev Med (1996) 4.36
Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol (2001) 1.23
Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer (2010) 1.20
Effect of posture on the metabolic clearance rate, plasma concentration and blood production rate of aldosterone in man. J Clin Endocrinol Metab (1968) 1.14
Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol (2001) 1.13
Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis. Sex Transm Dis (1999) 1.11
Mechanistic studies on aromatase and related C-C bond cleaving P-450 enzymes. J Steroid Biochem Mol Biol (1993) 1.02
Methyl angolensate: the antiulcer agent of the stem bark of Entandrophragma angolense. Planta Med (1995) 0.98
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat (1999) 0.95
Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer. J Med Chem (1998) 0.92
Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. J Steroid Biochem Mol Biol (1998) 0.91
Human breast cancer cells contain an error-prone DNA replication apparatus. Cancer Res (1998) 0.86
A method for the measurement of aldosterone in peripheral plasma using 3H-acetic anhydride. J Clin Endocrinol Metab (1967) 0.86
Biochemical assessment of limits to estrogen synthesis in porcine follicles. Biol Reprod (2003) 0.84
A unique form of proliferating cell nuclear antigen is present in malignant breast cells. Cancer Res (1998) 0.82
Regulation of microsomal P450, redox partner proteins, and steroidogenesis in the developing testes of the neonatal pig. Endocrinology (2002) 0.82
Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo. Br J Cancer (1999) 0.82
Cytochrome P450c17-expressing Escherichia coli as a first-step screening system for 17alpha-hydroxylase-C17,20-lyase inhibitors. Anal Biochem (1999) 0.82
Aromatase inhibitors and their application in breast cancer treatment*. Steroids (2000) 0.80
Aromatase inhibitors and breast cancer. Semin Oncol (1996) 0.79
Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds. Endocrinology (1999) 0.77
Antifertility activity of Quassia amara: quassin inhibits the steroidogenesis in rat Leydig cells in vitro. Planta Med (1995) 0.77
Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis. Br J Cancer (2000) 0.75
Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo. J Steroid Biochem Mol Biol (1999) 0.75
Biotransformation of progesterone to 14 alpha-hydroxypregna-1,4-diene-3,20-dione, a novel fungal metabolite, by Colletotrichum antirrhini. J Steroid Biochem (1985) 0.75
[Excellent achievement of "Huangdi Neijing". Part II (author's transl)]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao (1981) 0.75
Identification of human plasma proteins using the Laemmli method of gel electrophoresis. Biochem Soc Trans (1994) 0.75
[Excellent achievement of "Huangdi Neijing". Part I (author's transl)]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao (1980) 0.75
Selective 19-hydroxylase inhibition by an aromatase inhibitor, 4-hydroxyandrostenedione. Clin Physiol Biochem (1988) 0.75
Concerning the pathway from 19-oxoandrost-4-ene-3,17-dione to estrone. Steroids (1989) 0.75
Pharmacokinetic profile of 3beta-hydroxy-17-(1H-1,2,3-triazol-1-yl)androsta-5,16-diene (VN/87-1), a potent androgen synthesis inhibitor, in mice. J Steroid Biochem Mol Biol (2001) 0.75